Congenital Leukemia Cutis Misdiagnosed as Benign Neonatal Hemangiomatosis

> Quyn Sherrod, PGY4 UCLA/WLA VA Dermatology

> > .

## Birth History

- 3600-g female born at 38 1/7 weeks
- G2P0→1 mother via uncomplicated cesarian section (previous myomectomy)
- Numerous violaceous nodules on head, neck, groin > trunk and extremities at birth
- APGAR scores of 9 at 1 and 5 minutes


## **Hospital Course**

- Transferred to the NICU for further workup
- · Labs:
  - WBC 12.2 \_ Liver & renal function, coags normal
  - Hb 19 Platelets: 159 negative \_ TORCH serologies negative \_ Neuroblastoma markers (VMA, HVA)
- Imaging
   CXR normal
   Abdominal U/S normal
   ECHO normal \_ MRI head normal

3


## **Hospital Course**

- No dermatology consult obtained
- Presumptive diagnosis of benign neonatal hemangiomatosis given by primary team
- Discharged on 5th day of life
- · Presented to UCLA dermatology at day of life 21 with enlarging skin nodules



Discrete violaceous nodules on the scalp

5



Numerous large violaceous nodules on back, also purpuric patches

# Physical Examination





Labia majora with firm violaceous confluent nodules, purpuric macules

7

# Diagnostic Workup

- CBC at 21 days:
  - WBC: 266 with 73% blasts
  - Platelets: 53
- Peripheral smear: 92% blasts
- Flow cytometry:
  - 95% blasts
  - PAX 5 +, CD10 +, CD19 +, CD34 +, CD79 +
  - TdT –, CD117 -
  - + MLL gene rearrangement





Skin biopsy of scalp nodule was performed, and showed dermal infiltration by blastic cells c/w precursor b cell acute lymphoblastic leukemia/lymphoma.

#### Admission

- Diagnosis: Congenital B cell leukemia with leukemia cutis
- CSF: 95% blasts
- Bone marrow: 10% blasts
- · Induction chemotherapy:
  - Vincristine, cytoxan, asparaginase, & duanorubicin
  - Intrathecal MTX, cytarabine, hydrocortisone

Intrathecal for CNS disease

11

# **Hospital Course**

- Complicated by tumor lysis syndrome
  - Hyperuricemia, hyperkalemia
  - Required hemodialysis
- Cutaneous lesions began to regress 7 days into induction therapy
- Plan for stem cell transplant

Day 7 of Induction Therapy





13

Congenital Leukemia Cutis

#### Congenital Leukemia

- · Presents at birth or within first month of life
- Incidence: 1 per 5 million births
- Fewer than 200 cases reported
- 25% have leukemia cutis
  - Direct infiltration of skin/subQ by malignant
- Acute myelogenous leukemia (AML) is most common
  - Acute lymphoblastic leukemia (ALL) represents <10% cases</li>

Rare

15

## Presentation

- Hyperleukocytosis
- Hepatosplenomegaly
- · Central nervous system involvement
- · Leukemia cutis

  - 'Blueberry muffin baby'
     Multiple firm violaceous nodules on head and trunk
     Purpura, petechiae, echymoses

#### Pathogenesis of Congenital Leukemia

- Mixed lineage leukemia (MLL) gene
   Chromosome 11 band q23

  - Role in hematopoiesis
    Most commonly involved gene
    Rearranged in 80% congenital ALL, 60% AML

    Rearranged in 80% congenital ALL, 60% AML
- + MLL translocation → poorer prognosis

MLL: encodes a 431 Kda protein.

MLL rearrangements are rare In noninfant leukemias, but are seen in leukemias treated with chemo agents that target topoisomerases II

Maternal consumption of products that inhibit topoisomerases may contribute to the development of congenital leukemia

17

# Differential Diagnosis Blueberry Muffin Baby Induction of neonatal dermal erythropoiesis - Congenital infections - Rubella - Cossaccia virus - Cytomegalovirus - Tocoptemosis - ABJ or Francompatibility - Hereditaly spherocytosis Infiltrative cutaneous processes - Laukeria version of the control of

Neuroblastoma: blue firm nodules with persistent blanching after rubbing 2/2 local catecholamine release LCH: can present as nodules and purpura, but more commonly is diffuse blisters and pustules leading to erosions

### Congenital Leukemia Diagnostic Criteria

- 1. Presentation at birth or within first 4 weeks of life
- 2. Proliferation of immature white blood cells
- 3. Infiltration of immature white blood cells into extrahematopoietic tissue
- 4. Absence of other diseases mimicking leukemia cutis

Must meet all 4 diagnostic criteria

19

#### Treatment

- 3 phases:
  - Remission-induction phase
  - Glucocorticoid, vincristine, asparaginase, & an anthracycline

  - Consolidation phase
     High-dose MTX, 6-mercaptopurine

  - Continuation therapy
     Intrathecal MTX Q 3 months, vincristine Qmonth, 6-MP Qday & MTX Qweek
- Stem cell/bone marrow transplant
- Prevention of tumor lysis syndrome
- Hyperuricemia, hyperphosphatemia, hypocalcemia, hyperkalemia

goal of induction is to achieve remission or less than 5% blasts in the bone marrow. Induction therapy generally consists of 3-4 drugs

#### Anthracycline = duanorubicin

Consolidation therapy is given soon after remission is achieved to further reduce the leukemic cell burden before the emergence of drug resistance and relapse in sanctuary sites (ie, testes, CNS). In this phase of therapy, the drugs are given at doses higher than those used during induction or the patient is given different drugs (ie, high-dose MTX and 6-mercaptopurine [6-MP]), epipodophyllotoxins with cytarabine, or multiagent combination therapy. Consolidation therapy also appears to improve the long-term survival of patients with standard-risk disease


# Prognosis

- 23% survival at 24 months
- + MLL rearrangement → worse prognosis
- Must have high index of suspicion and low threshold to biopsy
- Consider other etiologies of 'blueberry muffin baby'
- Early cytogenetic analysis

21

## Our Patient...

- Recurrence of scalp nodule 3 months after induction chemotherapy
  - Biopsy proven leukemia
- Failed re-induction chemo-



· Now on comfort care measures



23

#### References

- Congenital acute lymphoblastic leukemia: report of a case with leukemia cutis. Akcakus M, et al. Clin Pediatr (Phila). 2004 Jun;43(5):487-90.
   Congenital leukemia cutis. Fender AB, et al. Pediatr Dermatol. 2008 Jan-Feb;25(1):34-7.
   Congenital leukemia cutis with subsequent development of leukemia. Zhang IH, et al. J Am Acad Dermatol. 2006 Feb;54(2 Suppl):S22-7.